Evogene and Zeraim Gedera Salt Tolerant Tomato Collaboration Advances to Second Phase
Evogene Ltd. and Zeraim Gedera Ltd, which was recently acquired by Syngenta S.A., announced that their joint program for the development of salt tolerant tomato varieties has successfully completed the first phase with experimental varieties currently undergoing field trials in target locations worldwide.
Under a recently signed follow-on agreement, the parties intend to further develop the experimental varieties towards commercialization and develop additional varieties for new target markets. The use of massive irrigation practices and water sources of high salinity levels in tomato growing areas have caused a reduction in tomato yield and in severe cases the abandoning of such areas. The tomato varieties developed through this collaboration are expected to allow growers to maintain high yields under severe growing conditions displaying high salt concentrations of water and soil.
Zeraim Gedera's breeding program is based on its tomato germplasm and utilizes Evogene's advanced selection tools. These selection tools include proprietary selection assays and molecular marker for salt tolerance, developed based on Evogene's computational gene discovery platform.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Heptares granted patents covering stabilised receptor technology in Europe and Japan - Key patent grants protect Heptares’ leading position in GPCR-targeted drug design and discovery
Pevion’s therapeutic Candida vaccine shows robust systemic and mucosal immunogenicity

Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics
Amarin corporation Appoints Colin W. Stewart as President and Chief Executive Officer
Discovery of quantum vibrations in 'microtubules' corroborates theory of consciousness

Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”
Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration

A sprinkle of platinum nanoparticles onto graphene makes brain probes more sensitive
Merck and Washington University working on diagnostics and treatment of malnutrition - Genome editing to be used in intestinal bacteria research
Biophage Pharma announces sale of Immunotox Labs Division to Validapro BioSciences Inc
